The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...

The evolving treatment landscape in polycythemia vera (PV) is shifting from a focus on hematocrit control to a more ...

To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ...

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork ...

FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...

The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...

Liquid biopsy ctDNA reveals targets and flags residual disease in esophageal and gastric cancers, hinting at earlier relapse ...

Dr. Premal Thaker reports IMNN-001 shows early survival benefit in ovarian cancer by activating immune response directly in ...

On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and ...